Abbott India - Sales Recovery In The Offing: ICICI Direct
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICICI Direct Report
While Abbott India Ltd.'s Q4 FY21 results are not strictly comparable on a YoY basis due to pandemic related challenges in the base year, FY21 revenues grew 5.3% YoY to Rs 4,310 crore likely moderated by the decline in 'Duphaston' (gynaecology) sales alongside demand slowdown in some other therapies amid the pandemic.
Ebitda margins expanded 290 basis points YoY to 21.4% with an overall better operational performance.
Ebitda for the fiscal grew 21.8% YoY to Rs 922 crore.
Profit after tax was up 16.5% YoY to Rs 691 crore in line with operational performance and lower other income.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.